Get the Daily Brief
Latest Biotech News
Psithera spins out of Roivant with $47.5M – new immunology small‑molecule shop
Psithera Inc. emerged from Roivant as an independent company with a $47.5 million Series A and new CEO Eric Shaff, repositioning the group to focus on small‑molecule immune and inflammatory...
Engineered co‑signaling receptors sharpen T‑cell precision: study
A team led by Cabezas‑Caballero and colleagues reported engineered co‑signaling receptors that improve T‑cell targeting precision and reduce off‑target cross‑reactivity. The study describes...
Autologous iPSC lung‑on‑a‑chip models early TB events: personalized platform
Researchers from the Francis Crick Institute and AlveoliX reported an autologous alveolus‑on‑a‑chip built entirely from iPSC‑derived cells from a single donor. Published in Science Advances, the...
Engineered IL‑10 targets LDL to cut vascular inflammation – study
A Nature Biomedical Engineering study engineered IL‑10 to target LDL particles and reported targeted delivery reduced vascular inflammation in preclinical atherosclerosis models. The approach...
AbbVie buys ex‑China rights to Zelgen’s DLL3 T‑cell engager – $1.1B pact
AbbVie signed a $1.1 billion deal to acquire ex‑China rights to Zelgen Biopharmaceuticals’ lead trispecific T‑cell engager, alveltamig (ZG‑006), targeting DLL3. Under the agreement announced Dec....
Transcenta licenses HiCB platform to EirGenix: CDMO collaboration for continuous biologics
Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, including continuous perfusion and integrated hybrid continuous...
Insilico posts big gains after Hong Kong listing – finance report
Insilico Medicine recorded a substantial market gain following its Hong Kong listing, according to a BioCentury finance report. The listing outcome boosted Insilico’s public valuation and...
Psithera exits Roivant, raises $47.5M to pursue immune and inflammatory small molecules
Psithera Inc. spun out from Roivant and closed a $47.5 million Series A financing while appointing Eric Shaff as president and CEO. The Watertown, Mass. company repositioned itself to develop...
Third FDA CRL derails Outlook’s ONS‑5010 – shares plunge
Outlook Therapeutics received a third complete response letter (CRL) from the U.S. Food and Drug Administration for ONS‑5010, its bevacizumab formulation for wet age‑related macular degeneration....
AML resistance tackled... palbociclib plus venetoclax shows durable activity
Researchers at Oregon Health & Science University reported that combining the CDK4/6 inhibitor palbociclib (approved in breast cancer) with venetoclax produced stronger, more durable anti‑leukemia...
AIM platform: single‑strand deaminase enables precise, tunable RNA edits
A new RNA‑editing technology, termed AIM (Adjustable RNA Information Manipulation), uses a single‑strand deaminase to enable controllable, site‑specific RNA editing, according to a Nature...
St. Jude method: better detection of base‑editor off‑targets
Scientists at St. Jude Children’s Research Hospital published a new method to detect small off‑target edits produced by base editors, addressing a major technical and safety challenge in precision...
Inherited variant curbs clonal hematopoiesis, reduces leukemia risk – Science
A GWAS meta‑analysis of more than 640,000 individuals, led by Vijay G. Sankaran’s lab at Harvard Medical School and published in Science, identified a rare noncoding variant (rs17834140‑T) that...
Engineered T cells gain precision – ex‑vivo platforms test immunotherapy
Two complementary advances target immunotherapy precision: first, researchers led by Cabezas‑Caballero engineered co‑signaling receptors that reduce T‑cell off‑target cross‑reactivity and improve...
AbbVie pays $1.1B — Gains ex‑China rights to Zelgen T‑cell engager
AbbVie signed a deal to acquire ex‑China rights to Zelgen Biopharmaceuticals’ trispecific T‑cell engager alveltamig (ZG‑006) in a pact valued at up to $1.1 billion. Under the agreement, AbbVie...
Third FDA CRL... Outlook Therapeutics’ ONS‑5010 rejected again
The FDA issued a third complete response letter (CRL) to Outlook Therapeutics for ONS‑5010, its bevacizumab biosimilar/formulation aimed at treating wet age‑related macular degeneration. The...
Transcenta licenses HiCB platform to EirGenix: upfronts and milestones
Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform to support continuous perfusion and integrated hybrid continuous...
Insilico posts big gain after Hong Kong listing – Finance report
Insilico Medicine recorded a strong market response following its Hong Kong listing, with finance reporting pointing to a notable post‑IPO valuation uptick. BioCentury’s finance roundup...
Psithera spins out of Roivant: $47.5M Series A and new CEO
Psithera Inc. completed a spin‑out from Roivant Sciences, rebranding from Psivant Therapeutics and announcing a $47.5 million Series A financing alongside the appointment of Eric Shaff as...
Neuro biotech Nido shuts down – Phase 2 readout disappoints
Nido Biosciences announced it will close after its lead neurological disease candidate failed to produce meaningful benefit in a midstage (phase 2) study. The company’s decision ends a five‑year...